Most partnerships don’t fail because of the business—they fail because the structure can’t support growth, misaligned incentives, or change over time. The right partnership doesn’t just work—it scales. At a high level, most partnerships look similar: shared upside, aligned incentives, and complementary capabilities. But in practice, the difference between a partnership that survives and one that drives long-term enterprise value comes down to structure. We’ve seen this across

Most cannabis deals don’t fail—they stall after signing. Learn the key execution risks around approvals, disclosures, and consents that determine whether your deal actually closes. Most deals don’t die — they stall. In cannabis transactions, signing the purchase agreement is not the finish line. It’s the beginning of the most fragile phase of the deal: execution . This is where timelines slip, approvals drag, issues surface, and momentum disappears. And once a deal stalls, it

Most cannabis deals don’t fail in negotiation—they fail in structuring. This blog breaks down how seemingly obvious considerations (ownership, real estate, and regulatory alignment) are sometimes overlooked, and ultimately determine whether your deal can close. Most cannabis deals do not fail because of poor negotiation. Instead, they fail because of how they are structured. On paper, many transactions seem solid: parties agree on price, sign contracts, and appear aligned. Bu